'Tip of the iceberg': Novartis-partnered UC Berkeley lab churns out a startup to tackle protein stabilization

Kyle LaHucik

Senior Reporter

For the past decade, Daniel Nomura’s lab at UC Berkeley has been working to find chemical approaches to drug the so-called “undruggable,” and with the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Tip of the iceberg': Novartis-partnered UC Berkeley lab churns out a startup to tackle protein stabilization

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Healthcare shakeup hits Washington, with cuts at CDC, NIH and other agencies

Exclusive: Drugmakers plan Trump meeting next week amid Washington health shakeups

Kojin Therapeutics shuts down, citing lack of investor interest and complex science

BioNTech vets raise $90M Series A for bispecific I&I startup

ARPA-H chief is out as Trump administration cuts health agencies

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

'Tip of the ice­berg': No­var­tis-part­nered UC Berke­ley lab churns out a start­up to tack­le pro­tein sta­bi­liza­tion

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'Tip of the iceberg': Novartis-partnered UC Berkeley lab churns out a startup to tackle protein stabilization